Health Care & Life Sciences » Biotechnology | Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
5,533.40
6,718.20
25,678.00
20,554.00
17,399.60
13,713.40
Other Current Assets
218.40
688.50
803.50
1,836.50
439.30
616.20
Total Current Assets
5,751.80
7,406.70
26,481.50
22,390.50
17,839.00
14,329.60
Net Property, Plant & Equipment
13.90
127.70
106.10
88.50
57.40
118.80
Total Investments and Advances
-
34.70
-
-
390.90
391.10
Other Assets
-
-
-
49.90
49.90
49.90
Total Assets
5,765.70
7,569.10
26,587.60
22,528.90
18,337.10
14,889.40
ST Debt & Current Portion LT Debt
6,865.10
283.60
265.70
-
-
Accounts Payable
-
-
-
-
4,650.10
Other Current Liabilities
460.10
9,208.10
4,347.80
4,520.60
15.90
Total Current Liabilities
7,325.20
9,491.60
4,613.50
4,520.60
4,666.00
Total Liabilities
7,325.20
9,491.60
4,613.50
4,520.60
4,666.00
Common Equity (Total)
1,559.50
1,922.50
21,974.00
18,008.30
13,671.10
Total Shareholders' Equity
1,559.50
1,922.50
21,974.00
18,008.30
13,671.10
Total Equity
1,559.50
1,922.50
21,974.00
18,008.30
13,671.10
Liabilities & Shareholders' Equity
5,765.70
7,569.10
26,587.60
22,528.90
18,337.10

About Actinium Pharmaceuticals

View Profile
Address
275 Madison Avenue
New York New York 10016
United States
Employees -
Website http://www.actiniumpharmaceuticals.com
Updated 07/08/2019
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M.